Adverum Biotechnologies, Inc. (ADVM)
$4.36+0.00%Close
BUYRECOVERY · day 3
Key stats
- Market cap
- $96M
- Beta
- 0.87
- P/E (TTM)
- -1.00
- 1W
- +4.81%
- 1M
- +0.93%
- vs SPY 1W
- +4.95%
- vs SPY 1M
- -1.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 9
- GROWTH
- 35
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC153.2%
REV YoY-
ROE255.3%
EPS YoY-
ROA-133.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.00
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-1.84
P/FCF-
EV/EBITDA-1.66
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.65
ND/EBITDA-
BETA0.87
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ADVM?
- LOPJLB’s latest quantitative signal on Adverum Biotechnologies, Inc. (ADVM) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is ADVM in?
- Adverum Biotechnologies, Inc. (ADVM) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Adverum Biotechnologies, Inc. (ADVM) do?
- Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. …